Pacritinib

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Pacritinib
Pacritinib skeletal.svg
Clinical data
Synonyms SB1518
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C28H32N4O3
Molar mass 472.58 g/mol
3D model (JSmol)

Pacritinib (INN[1]) is a macrocyclic Janus kinase inhibitor that is being developed for the treatment of myelofibrosis. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3 (FLT3). The drug was in Phase III clinical trials as of 2013.[2] The drug was discovered in Singapore at the labs of S*BIO Pte Ltd. It is a potent JAK2 inhibitor with activity of IC50 = 23 nM for the JAK2WT variant and 19 nM for JAK2V617F with very good selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, respectively).[3][4]

The drug was acquired by Cell Therapeutics, Inc. (CTI) and Baxter International and could effectively address an unmet medical need for patients living with myelofibrosis who face treatment-emergent thrombocytopenia on marketed JAK inhibitors.[5] When Shire Pharmaceuticals purchased Baxalta, a spin-off of Baxter Pharmaceuticals, they halted the development of the drug and ended their partnership with CTI.[6][7]

The drug was given fast-track status in 2014.[8] In 2016, the FDA placed a full clinical hold on pacritinib due to concerns about increased mortality in patients receiving the drug in the "PERSIST-2" trial.[9] The clinical hold was lifted in January 2017.[10]

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN) List 104" (PDF). WHO Drug Information. 24 (4): 386. 2010. 
  2. ^ "JAK-Inhibitoren: Neue Wirkstoffe für viele Indikationen". Pharmazeutische Zeitung (in German) (21). 2013. 
  3. ^ William, A. D.; Lee, A. C. -H.; Blanchard, S. P.; Poulsen, A.; Teo, E. L.; Nagaraj, H.; Tan, E.; Chen, D.; Williams, M.; Sun, E. T.; Goh, K. C.; Ong, W. C.; Goh, S. K.; Hart, S.; Jayaraman, R.; Pasha, M. K.; Ethirajulu, K.; Wood, J. M.; Dymock, B. W. (2011). "Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma". Journal of Medicinal Chemistry. 54 (13): 4638–58. doi:10.1021/jm200326p. PMID 21604762. 
  4. ^ Poulsen, A.; William, A.; Blanchard, S. P.; Lee, A.; Nagaraj, H.; Wang, H.; Teo, E.; Tan, E.; Goh, K. C.; Dymock, B. (2012). "Structure-based design of oxygen-linked macrocyclic kinase inhibitors: Discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)". Journal of Computer-Aided Molecular Design. 26 (4): 437–50. doi:10.1007/s10822-012-9572-z. PMID 22527961. 
  5. ^ http://www.pmlive.com/pharma_news/baxter_licenses_cancer_drug_from_cti_in_$172m_deal_519143
  6. ^ http://www.ctibiopharma.com/pipeline/pacritinib/
  7. ^ http://www.in-pharmatechnologist.com/Regulatory-Safety/Shire-ends-pacritinib-development-deal-with-CTI-post-Baxalta-merger
  8. ^ http://www.fiercebiotech.com/biotech/struggling-cti-reveals-new-pacritinib-data-misses-a-primary-endpoint
  9. ^ http://www.streetinsider.com/Corporate+News/CTI+BioPharmas+(CTIC)+Pacritinib+Placed+on+Full+Clinical+Hold%3B+NDA+Withdrawn/11297746.html
  10. ^ "CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib". PR Newswire. Retrieved 18 April 2017.